



ADVANCING SCIENCE
FOR BETTER HEALTH

MedImmune is committed to advancing science to develop better medicines that help people live healthier, longer and more satisfying lives.

 **MedImmune**

Our Company



MedImmune, a leading biotechnology company wholly owned by AstraZeneca plc, is dedicated to advancing science and medicine to help people live better lives. Our company has historically been committed to developing novel drug compounds within the areas of infectious disease, with a focus on pediatric conditions, inflammatory disease and oncology.

PREVENTING INFECTIOUS DISEASE

As the industry leader in developing breakthrough products to help prevent pediatric respiratory infectious diseases, MedImmune has substantially contributed to the health and well-being of infants and children worldwide. Our success to date has come from the introduction of antibodies, such as Synagis® (palivizumab) to help prevent serious respiratory syncytial virus (RSV)—a viral pathogen that produces annual outbreaks usually between fall and spring. Thus far, Synagis has been used to help prevent RSV disease globally in more than one million babies.

MedImmune has also developed FluMist® (Influenza Virus Vaccine Live, Intranasal), a nasal spray influenza vaccine for children as young as two years of age and adults through 49 years of age. This marks the first innovation in influenza vaccine technology in more than 60 years.

Please see Important Safety Information later in this brochure.

THERAPEUTIC AREAS OF CONCENTRATION

MedImmune researchers are currently advancing multiple therapies that may have the potential to help prevent various respiratory conditions and other inflammatory diseases.

Researchers and scientists, from a biologics company in Cambridge, England that is now part of MedImmune, led the development of Humira®* (adalimumab), a monoclonal antibody (MAb) called a tumor necrosis factor (TNF) blocker that is approved for use in several inflammatory conditions.**


AstraZeneca's 2007 acquisition of MedImmune advances research into new areas that seek to address unmet therapeutic needs within cardiovascular and metabolic disease; pain and central nervous system disorders and gastrointestinal disease as well as an expanded oncology drug candidate portfolio.

R&D — INVESTING FOR THE FUTURE

MedImmune is passionate about pediatric health, and it has a long-standing commitment to investing in research and development. The bar graph below reinforces that commitment as MedImmune's investment is intended to continue through the foreseeable future.

MEDIIMMUNE RESEARCH AND DEVELOPMENT

(DOLLARS IN MILLIONS)



*Humira® is a registered trademark of Abbott Laboratories

**Humira [prescribing information] Abbott Laboratories. January 2008.

Our Community



Since 2004, close to a third of MedImmune's annual revenue has been reinvested back into research and development, resulting in one of the most robust biologics pipelines within the entire bio-pharma industry.

Based on data from the *2007 EU Industrial R&D Investment Report*, MedImmune's level of pediatric R&D investment is unsurpassed by any other biotechnology company. MedImmune has also invested the second highest percentage of sales on R&D among large* biotech companies for the past three years. For the last two years of the study, MedImmune was second overall among large biotech companies in its amount of R&D dollars spent per employee. Given its pediatric focus, coupled with the largest pediatric sales force within the biotech space, it is clear that MedImmune continues to lead the way for this underserved patient base.

NEW TECHNOLOGIES – UNFOLDING THE FUTURE

MedImmune continues to be an innovation leader among biotechnology companies, making new therapeutic discoveries that hold the potential to help current and future generations lead better lives. Sample technologies include:

- **Polyspecific MABs** – monoclonal antibodies that target two or more pathogens at a time
- **Virus-like particle (VLP) technology** – used to develop world's first vaccine against human papillomavirus (HPV) to help prevent cervical cancer

- **Peptide derivatives** – new amino acid chains that enhance the way cells fight foreign invaders
- **siRNA therapies** – the latest method to identify and suppress gene activity

PEDIATRIC COMMUNITY – SUPPORTING FUTURE RESEARCHERS

Each year, MedImmune invests millions of dollars into continuing education, clinical programs and other grants that help increase the understanding of various childhood conditions as well as foster the next generation of pediatric researchers.

For example, MedImmune annually sponsors a pediatric fellowship grant program that supports trainees enrolled in accredited programs through the American Board of Pediatrics. Annually, MedImmune provides more than \$200,000 that is awarded to six fellows, each of whom receives a grant of \$35,000 toward pediatric viral respiratory research projects.

LOCAL COMMUNITY – RAISING AWARENESS

An ancient proverb states "Awareness is the key to change." MedImmune takes this philosophy to heart with its community relations efforts and outreach, intended to educate and elevate awareness of pediatric health issues including:

- Healthcare access for children
- Local immunization policies and barriers
- Preventive steps against infectious diseases
- The burden of an infant's disease on the child's family and the local healthcare system
- Pandemic flu preparedness

* Minimum of 2,000 employees



MedImmune supports a spectrum of pediatric-focused organizations and local agencies including:

Families Fighting Flu: This independent non-profit is comprised of a group of families and pediatricians who have experienced first-hand the loss of a child or have had a child experience severe medical complications from the flu. The organization strives to reduce pediatric deaths due to the flu by raising awareness about the importance of vaccinating children.

Thrive Network: This volunteer program is wholly supported and funded via MedImmune and includes approximately 400 parent advocates united to help raise awareness about RSV and contributing risk factors.

March of Dimes: MedImmune has partnered with the March of Dimes for several years on a variety of initiatives including national **Prematurity Awareness Day** and **NICU Family Support**,sm a national multi-year, \$750,000 program providing information and on-site comfort to families whose children are in neonatal intensive care units (NICUs).

Premie Health Coalition: This non-profit consortium of more than 25 national organizations has assembled to lend its influence and expertise on behalf of premature infants who cannot advocate for themselves.

LOCAL COMMUNITY – FURTHERING EDUCATION

Beyond the NICU, emergency and hospital waiting rooms, MedImmune also sponsors programs for the classroom as a way to encourage future scientists and researchers.

Science Education Initiatives: MedImmune sponsors and hosts “Young Women in Bio,” a career exploration event to encourage middle school-aged girls to consider careers in science and entrepreneurship.

Child-Focused Community Service: MedImmune regularly conducts child-focused community service projects at its national meetings. In June 2007, more than 600 employees built a new 7,000-square foot playground at the Palomar Family YMCA in Escondido, California.

Regional Science Fair Sponsorship: MedImmune sponsors high school science fairs in communities where its facilities are located and presents the “Advancing Science for Better Health” award to deserving students.

PATIENT ASSISTANCE

MedImmune is proud to offer the **MedImmune Assistance Program (MAP)**, which is designed to provide assistance to individuals who need access to Synagis but lack health insurance. The program is administered as part of the Synagis Reimbursement Hotline and can be reached by calling 1-877-480-8082. A healthcare provider can review the patient’s eligibility with a program specialist.

In addition, MedImmune supports **The Patient Access Network Foundation (PANF)**, which is an independent, non-profit 501(c)(3) organization dedicated to supporting the needs of patients who cannot afford the treatments they need due to out-of-pocket healthcare costs. More information about the help that’s available for RSV prevention and treatment can be found by visiting www.patientaccessnetwork.org.

Our Products



PRODUCT INFORMATION

For two decades, MedImmune and its employees have upheld the promise of advancing science and have turned innovation into medical solutions for better pediatric health. That commitment will continue for the sake of our future generations.

Synagis® (palivizumab)

Synagis is the first monoclonal antibody successfully developed to combat an infectious disease, and is indicated for the prevention of serious lower respiratory tract disease caused by RSV in children at high risk of serious RSV disease.



RSV is the most common cause of respiratory hospitalization in children under the age of one. Approximately two-thirds of all infants are infected with RSV during the first year of life, and nearly all children have been infected at least once by the time they reach their second birthday.

Synagis, when administered to high-risk infants, has previously shown a 55-percent reduction in hospitalizations due to RSV.

RSV infection usually manifests as an upper respiratory tract infection with symptoms resembling a cold. In preterm and other high-risk infants, however, the infection has an increased risk of progressing to a lower respiratory tract infection that sometimes requires hospitalization, mechanical ventilation and intensive care.

Please see important safety information and complete prescribing information enclosed within this brochure.

FluMist® (Influenza Virus Vaccine Live, Intranasal)



FluMist is the first nasal flu vaccine that helps prevent the flu where the flu virus typically enters the body—the nose.

Other FluMist firsts include the first advancement in influenza vaccine technology since 1945, and the first nasally administered vaccine for any disease approved by the U.S. Food & Drug Administration.

FluMist is a live attenuated, trivalent influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

Do not administer FluMist to children less than 24 months of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials.

The flu is a contagious respiratory illness caused by influenza viruses. It can cause mild to severe illness, and the best way to help prevent the flu is by getting a flu vaccination each year.

According to the U.S. Centers for Disease Control and Prevention, every year in the United States, on average more than 200,000 people are hospitalized from flu complications, and about 36,000 people die from flu.

Please see important safety information and complete prescribing information enclosed within this brochure.



Important Safety Information: Synagis

Synagis® (palivizumab) is indicated for the prevention of serious lung infections caused by respiratory syncytial virus (RSV) in children at high risk of RSV disease. Synagis is given as a shot, usually in the thigh muscle, each month during the RSV season. The first dose of Synagis should be given before RSV season begins. Children who develop an RSV infection while receiving Synagis should continue the monthly dosing schedule throughout the season. Synagis has been used in more than one million children in the U.S. since its introduction in 1998.

Very rare cases (<1 per 100,000 patients) of severe allergic reactions such as anaphylaxis and rare (<1 per 1,000 patients) hypersensitivity reactions have been reported with Synagis. These rare reactions may occur when any dose of Synagis is given, not just the first one. Also, rare but serious side effects can occur, which may lead to unusual bruising and/or groups of pinpoint red spots found on the skin.

Other side effects with Synagis may include upper respiratory tract infection, ear infection, fever and runny nose. In children born with heart problems, Synagis was associated with reports of low blood oxygen levels and abnormal heart rhythms. Synagis should not be used in patients with a history of a severe prior reaction to Synagis or its components. Side effects, such as, skin reactions around the area where the shot was given (like redness, swelling, warmth or discomfort) can also occur.

Please see complete prescribing information enclosed within this brochure and at www.synagis.com.

Important Safety Information: FluMist

FluMist® is a live attenuated, trivalent influenza virus vaccine indicated for active immunization of individuals two to 49 years of age against influenza disease caused by influenza virus subtypes A and type B contained in the vaccine.

FluMist is contraindicated in individuals with history of hypersensitivity to eggs, egg proteins, gentamicin, gelatin or arginine or with life-threatening reactions to previous influenza vaccinations, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

Do not administer FluMist to children less than 24 months of age due to an increased risk of hospitalization and wheezing that was observed in clinical trials. FluMist should not be administered to any individual with asthma and to children less than five years of age with recurrent wheezing unless the potential benefit outweighs the potential risk. Do not administer FluMist to individuals with severe asthma or active wheezing.

If Guillain-Barré syndrome has occurred with prior influenza vaccination or if an individual is immunocompromised, the decision to give FluMist should be based on careful consideration of the potential benefits and risks. FluMist should not be administered to individuals with underlying medical conditions predisposing them to wild-type influenza infection complications unless the potential benefit outweighs the potential risk.

Most common adverse reactions (occurring at greater than or equal to 10 percent in individuals receiving FluMist and at least five percent greater than in placebo) are runny nose or nasal congestion in recipients of all ages, fever greater than 100 degrees Fahrenheit in children two-to-six years of age and sore throat in adults.

FluMist may not protect all individuals receiving the vaccine. FluMist is for intranasal administration only.

Please see complete prescribing information enclosed within this brochure and at www.flumist.com.

ABOUT MEDIMMUNE

MedImmune strives to provide better medicines to patients, new medical options for physicians and rewarding careers to employees. Dedicated to advancing science and medicine to help people live better lives, the company is focused on cardiovascular/gastrointestinal disease, neuroscience, oncology, infection, respiratory disease and inflammation. With approximately 3,000 employees worldwide and headquarters in Maryland, MedImmune is wholly owned by AstraZeneca plc (LSE:AZN.L, NYSE:AZN). For more information, visit MedImmune's website at <http://www.medimmune.com>.



ONE MEDIMMUNE WAY
GAITHERSBURG, MD 20878
TEL (301) 398-0000
FAX (301) 398-9000

WWW.MEDIMMUNE.COM

FLU08-023
SYN08-013